retatrutide mechanism triple agonist glp-1 gip glucagon ly3437943 Agonism Based Therapies for Obesity | Current Cardiovascular Risk Reports Beyond GLP-1: Retatrutide's triple-agonist mechanism

3.2 From single-target optimization to rational polypharmacology Another major shift influencing the relevance of underexplored peptide systems is the growing acceptance of rational polypharmacology

Diabetes (2018) 67

In 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% over a mean 39.8-month follow-up

Researchers acknowledge that it is possible that SGLT2is could also help reduce depression risk

[DOI] [PubMed] [Google Scholar] [53].U.S.F.a.D

Together, these two pathways create a multi-layered approach to appetite control that phentermine simply cannot match